brian_mcnamara

GSK appoints Brian McNamara chief of consumer health division

pharmafile | September 29, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brian McNamara, Emma Walmsley, GlaxoSmithKline 

GlaxoSmithKline PLC has named Brian McNamara the head of its consumer-health division. The new comes a week after the announcement of Emma Walmsley’s promotion to CEO of the UK-based pharmaceutical company. The announcement indicates that Brian will take up his appointment immediately, reporting to Andrew Witty before Walmsley takes up the post in March 2017.

McNamara previously oversaw business in Europe and the Americas at Glaxo’s consumer-health division, after only joining a year previously from Novartis AG during the completion of a three-part asset swap with the Swiss drugmaker. Prior to joining GSK, Brian spent eleven years at Novartis and sixteen years at Procter & Gamble.

McNamara commented upon his appointment, saying: “I am very excited about the opportunity to lead the Consumer Healthcare business at GSK.  We have an amazing opportunity ahead of us to deliver on our promise to consumers and grow our business to further extend our position as a leading, global consumer healthcare company”.

Advertisement

Andrew Witty also released a statement: “With his significant experience and expertise, Brian is the clear choice to build on the current momentum we are seeing in our business and fully maximise the future opportunities we have with our brands and to deliver the benefits of the integration.”

Related Content

GSK building

GSK and Vir Biotechnology COVID-19 drug found to reduce deaths and hospitalisation by 85%

Vir Biotechnology and GSK have announced that their monoclonal-antibody drug has been found to reduce …

GSK and CureVac sign £132m deal to develop next-generation COVID-19 vaccine

GlaxoSmithKline (GSK) and CureVac have today announced they are joining forces to develop a new …

NICE recommends GSK’s ZEJULA for advanced ovarian cancer

NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for …

The Gateway to Local Adoption Series

Latest content